Skip to main content
Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · Real-Time Price · USD
0.0782
+0.0014 (1.82%)
At close: Aug 13, 2025, 4:00 PM
0.0760
-0.0022 (-2.81%)
Pre-market: Aug 14, 2025, 8:36 AM EDT

Adaptimmune Therapeutics Revenue

Adaptimmune Therapeutics had revenue of $13.68M in the quarter ending June 30, 2025, a decrease of -89.33%. This brings the company's revenue in the last twelve months to $65.09M, down -53.99% year-over-year. In the year 2024, Adaptimmune Therapeutics had annual revenue of $178.03M with 195.34% growth.

Revenue (ttm)
$65.09M
Revenue Growth
-53.99%
P/S Ratio
0.31
Revenue / Employee
$128,626
Employees
506
Market Cap
20.73M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024178.03M117.75M195.34%
Dec 31, 202360.28M33.13M122.05%
Dec 31, 202227.15M21.00M341.50%
Dec 31, 20216.15M2.19M55.36%
Dec 31, 20203.96M2.84M252.76%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 422.82B
Johnson & Johnson 90.63B
Merck & Co. 63.62B
AbbVie 58.33B
AstraZeneca 56.50B
Novartis AG 55.19B
Eli Lilly and Company 53.26B
Novo Nordisk 49.11B
Revenue Rankings

ADAP News

More News